Phase IIa Clinical Trial Of Curcumin For The Prevention Of Colorectal Neoplasia
Notes for this study:
|Number of Subjects
In a non-randomized open label study, 2g and 4g of curcumin over the period of 30 days was able to reduce the amount of aberrant crypt foci in colorectal tissue only at the 4g dosage.
Patients were those with already present aberrant crypt foci and smokers, and without the usage of other anti-inflammatories.